Medpace Holdings, Inc. (MEDP)
- Previous Close
296.03 - Open
304.40 - Bid 311.32 x 100
- Ask 314.22 x 100
- Day's Range
301.80 - 314.08 - 52 Week Range
250.05 - 459.77 - Volume
188,839 - Avg. Volume
513,405 - Market Cap (intraday)
8.994B - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
23.87 - EPS (TTM)
13.11 - Earnings Date Jul 21, 2025 - Jul 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
300.30
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
www.medpace.com5,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MEDP
View More
Performance Overview: MEDP
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDP
View MoreValuation Measures
Market Cap
8.51B
Enterprise Value
8.19B
Trailing P/E
22.60
Forward P/E
24.10
PEG Ratio (5yr expected)
3.40
Price/Sales (ttm)
4.37
Price/Book (mrq)
14.33
Enterprise Value/Revenue
3.80
Enterprise Value/EBITDA
16.88
Financial Highlights
Profitability and Income Statement
Profit Margin
19.31%
Return on Assets (ttm)
15.44%
Return on Equity (ttm)
65.82%
Revenue (ttm)
2.16B
Net Income Avi to Common (ttm)
416.39M
Diluted EPS (ttm)
13.11
Balance Sheet and Cash Flow
Total Cash (mrq)
441.44M
Total Debt/Equity (mrq)
25.33%
Levered Free Cash Flow (ttm)
433.28M
Research Analysis: MEDP
View MoreResearch Reports: MEDP
View MoreLowering target price to $303.00
MEDPACE HOLDINGS INC has an Investment Rating of HOLD; a target price of $303.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $322.00
MEDPACE HOLDINGS INC has an Investment Rating of HOLD; a target price of $322.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetPositive Long-Term Outlook for Narrow-Moat Medpace Despite Macroeconomic Pressure in Near Term
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
RatingPrice TargetLowering target price to $296.00
MEDPACE HOLDINGS INC has an Investment Rating of HOLD; a target price of $296.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target